NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it hosted a key opinion leader webinar this week titled "The Graft-versus-Host Disease Exchange – Expert Perspectives on Evolving Clinical Practice” with leading pediatric transplant and cellular-therapy specialist Dr. Susan Prockop, Associate Professor, Harvard Medical School; Attending Physician & Director, Boston Children's Hospital. Dr. Prockop provided an overview of Ryoncil® (remestemcel-L-rknd)1 as a new treatment paradigm in the management of acute graft-versus-host disease, its use as first line after steroids, highlighted case studies, and discussed results from…